Skip to main content
. 2021 May 27;41(5):BSR20204203. doi: 10.1042/BSR20204203

Figure 1. Orlistat increases the therapeutic effects of enzalutamide on PC3 cells.

Figure 1

(A) A total of 5 × 103 PC3 cells/well were seeded into a 96-well plate. The next day, cells were treated with different doses of orlistat alone, enzalutamide alone and a combination of orlistat plus enzalutamide for 48 h. The cell viabilities were evaluated with an AlamarBlue assay. The calculated IC50 of orlistat alone, enzalutamide alone and combination treatment (COMB) were 80, 100 and 35 µM, respectively, in PC3 cells. (B) Quantification of (A). All experiments were repeated at least three times. ***P<0.001 vs. orlistat alone. $P<0.05 and $$$P<0.001 vs. combination and enzalutamide alone.